Amgen Inc.

AMGN

US0311621009

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

Pharmaceuticals

Calendar

2024-05-20 - American Thoracic Society Conference

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Amgen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

277.4 USD

Average target price

302.9 USD

Spread / Average Target

+9.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AMGEN INC.	-3.34%	149B
ELI LILLY AND COMPANY	+29.68%	699B
NOVO NORDISK A/S	+25.07%	571B
JOHNSON & JOHNSON	-4.35%	364B
MERCK & CO., INC.	+17.65%	326B
ABBVIE INC.	+3.77%	286B
ASTRAZENECA PLC	+14.68%	236B
NOVARTIS AG	+4.71%	198B
ROCHE HOLDING AG	-12.43%	194B
PFIZER, INC.	-3.79%	154B

Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
278.4 ^USD	+0.37%		+1.97%	-3.34%

May. 02	Amgen Expects Full-Year 2024 Share Repurchases Not to Exceed $500 Million	MT
May. 02	Amgen Q1 Non-GAAP Earnings Decline, Revenue Increases; Adjusts Full-Year Guidance; Shares Advance After Hours	MT

Amgen Expects Full-Year 2024 Share Repurchases Not to Exceed $500 Million	May. 02	MT
Amgen Q1 Non-GAAP Earnings Decline, Revenue Increases; Adjusts Full-Year Guidance; Shares Advance After Hours	May. 02	MT
Amgen Posts Higher 1Q Revenue, Swings to Loss	May. 02	DJ
Earnings Flash (AMGN) AMGEN Reports Q1 EPS $3.96, vs. Street Est of $3.89	May. 02	MT
Earnings Flash (AMGN) AMGEN Reports Q1 Revenue $7.45B, vs. Street Est of $7.453B	May. 02	MT
Amgen Guides For Full Year 2024 EPS of $19-$20.20 on Revenue of $32.5-$33.8 Billion, vs CIQ Analyst Consensus of $19.53/Share on Revenue of $32.9 Billion	May. 02	MT
Amgen first-quarter profit dips 1%, revenue rises 22%	May. 02	RE
Equity Markets Higher Ahead of Apple Earnings	May. 02	MT
S&P 500, Nasdaq Rise Intraday Amid Moderna Rally as Traders Await Apple Results	May. 02	MT
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple...	May. 02
Stock Futures Gain Pre-Bell as Fed Leaves Key Rate Unchanged; Asia, Europe Churn	May. 02	MT
European Midday Briefing : Stocks Steady as Powell Suggests Rate Hike Unlikely	May. 02	DJ
Chimeric Therapeutics Appoints COO; Shares Rise 4%	May. 01	MT
Amgen investors await weight-loss drug data	May. 01	RE
Amgen investors await weight-loss drug data	May. 01	RE
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...	Apr. 30
Sector Update: Health Care Stocks Mixed Premarket Tuesday	Apr. 30	MT
Amgen Reaches Deal to Resolve Patent Disputes With Sandoz	Apr. 30	MT
Sandoz Reaches Agreement With Amgen Resolving All Patent Litigation	Apr. 30	DJ
Sandoz Group Settles Patent Disputes with Amgen	Apr. 30	MT
Wall Street: buoyed by Tesla, confident ahead of FOMC meeting	Apr. 30	CF
Sandoz reaches agreement with Amgen over patent dispute	Apr. 30	RE
Wall Street: buoyed by Tesla, confident ahead of FOMC meeting	Apr. 29	CF
Earnings, Tech Outlooks Lift Wall Street Pre-Bell; Asia, Europe Up	Apr. 29	MT
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe	Apr. 26	MT